A Multi-Center Evaluation of the Long-Term Safety and Efficacy of SPK-8011 [Adeno-Associated Viral Vector With B-Domain Deleted Human Factor VIII Gene] in Males With Hemophilia A

Trial Profile

A Multi-Center Evaluation of the Long-Term Safety and Efficacy of SPK-8011 [Adeno-Associated Viral Vector With B-Domain Deleted Human Factor VIII Gene] in Males With Hemophilia A

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs SPK 8011 (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Spark Therapeutics
  • Most Recent Events

    • 16 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top